COMP <GO>
UTMD vs PROF // ENTERPRISE SCALE & MARKET CAP
Utah Medical Products Inc. (NASDAQ) VS. Profound Medical Corp. (NASDAQ) • 15-METRIC TALLY: UTMD 4
— PROF 5
▲ ENTERPRISE SCALE & MARKET CAP LEADER: PROF
LAST: $68.08 (+1.91%) • MKT CAP: $212.7M
market-cap
$212.7M
LAST: $6.57 (+12.12%) • MKT CAP: $214.1M
market-cap
$214.1M
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (UTMD VS. PROF)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | UTMD | PROF | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 57.10% | 70.80% | -13.70 | PROF | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 26.90% | -35.00% | +61.90 | UTMD | /roic <GO> |
| EV/EBITDA & P/E Valuation | 10.8x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 6.73% | -17.93% | +24.66 | UTMD | /fcf-yield <GO> |
| Operating Margin | 29.60% | -60.00% | +89.60 | UTMD | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -5.80% | 65.30% | -71.10 | PROF | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.87% | 0.00% | +1.87 | UTMD | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.97 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 5/9 | -1.00 | PROF | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 27.2 | 47.0 | -19.80 | PROF | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $212.7M | $214.1M | -$1.4M | PROF | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | UTMD REV | PROF REV | UTMD GROSS % | PROF GROSS % | UTMD FCF | PROF FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $38.5M | $16.1M | 57.1% | 70.8% | $14.3M | -$38.4M |
| FY 2024 | $40.9M | $9.7M | 59.0% | 72.2% | $14.6M | -$23.5M |
| FY 2023 | $50.2M | $5.9M | — | — | $22.3M | -$22.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
UTMD // BETA —
PROF // BETA —